The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real world outcomes of sequential ADC therapy in metastatic breast cancer: Patients treated with sacituzumab govitecan and trastuzumab deruxtecan.
 
Nicholas Mai
Stock and Other Ownership Interests - Gilead Sciences
Honoraria - IntegrityCE
Travel, Accommodations, Expenses - MJH Life Sciences
 
Miriam Klar
No Relationships to Disclose
 
Emanuela Ferraro
No Relationships to Disclose
 
Maria Bromberg
No Relationships to Disclose
 
Yuan Chen
No Relationships to Disclose
 
Pedram Razavi
Stock and Other Ownership Interests - Odyssey Biosciences
Honoraria - Daiichi Sankyo/Astra Zeneca; Pfizer
Consulting or Advisory Role - AstraZeneca; bioTheranostics; Epic Sciences; Guardant Health; Loxo/Lilly; Myriad Genetics; NeoGenomics Laboratories; Novartis; PAIGE.AI; Prelude Therapeutics; SAGA Diagnostics; Tempus
Research Funding - AstraZeneca (Inst); Biovica (Inst); Epic Sciences (Inst); GRAIL (Inst); Guardant Health (Inst); Hologic/Biotheranostics (Inst); Illumina (Inst); Invitae (Inst); Myriad Genetics (Inst); NeoGenomics Laboratories (Inst); Novartis (Inst); Tempus (Inst)
 
Shanu Modi
Honoraria - AstraZeneca; Daiichi Sankyo/Astra Zeneca; DualityBio; Genentech; Gilead Sciences; Seagen
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; DualityBio; Genentech; Gilead Sciences; GlaxoSmithKline; Lilly; Macrogenics; Puma Biotechnology; Seagen; Zymeworks
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); DualityBio (Inst); Nuvation Bio (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Sarat Chandarlapaty
Stock and Other Ownership Interests - Odyssey Biosciences; Totus Medicines
Consulting or Advisory Role - AstraZeneca/MedImmune; Boxer Capital; Inivata; Lilly; Novartis; Paige.ai; Prelude Therapeutics; SAGA Diagnostics; Sanofi
Research Funding - Ambryx (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Novartis (Inst); Paige.ai (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending for (1) targeting mutant ER with ER PROTACS and (2) targeting CDK4/6 with CDK4/6 PROTACS (Inst)
Travel, Accommodations, Expenses - Novartis Institutes for BioMedical Research
Other Relationship - Peerview; Targeted Oncology; WebMD
(OPTIONAL) Uncompensated Relationships - Odyssey Biosciences; Totus Medicines
 
Elaine M. Walsh
Consulting or Advisory Role - DeciBio; Seagen
 
Joshua Z. Drago
Honoraria - Intellisphere
Consulting or Advisory Role - AmMax Bio; AstraZeneca; GenagonTherapeutics; Launchpad Therapeutics; NuProbe
Research Funding - AstraZeneca (Inst); Bolt Biotherapeutics (Inst)